Primary Immune Thrombocytopenia (ITP)

Hematology·MeSH: Purpura, Thrombocytopenic, Idiopathic

Prevalence

30.0 / 100K

7 drugs in development·4 companies·8 clinical trials

Drug Pipeline by Phase

Phase 4(1)
DrugCompany
ianalumabNovartis AG (NVS)

Compare drugs

hmpl-523 vs ianalumabhmpl-523 vs thrombopoietin receptor agonist

Frequently asked questions

How many drugs are in development for Primary Immune Thrombocytopenia (ITP)?

BioSniper tracks 7 drugs in development for Primary Immune Thrombocytopenia (ITP) across 4 companies.

How many clinical trials target Primary Immune Thrombocytopenia (ITP)?

There are 8 clinical trials targeting Primary Immune Thrombocytopenia (ITP) tracked by BioSniper.

What is the prevalence of Primary Immune Thrombocytopenia (ITP)?

The estimated prevalence of Primary Immune Thrombocytopenia (ITP) is approximately 30.0 per 100,000 population.

Deep-dive into Primary Immune Thrombocytopenia (ITP)

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Primary Immune Thrombocytopenia (ITP) — Drugs in Development & Clinical Trials | BioSniper